For years, it was all about diet, exercise and lifestyle
Major drivers include aging populations in developed markets and rising skincare consciousness among younger demographics
[3] NAD+-dependent/-consuming enzymes modify proteins post-translationally in various cellular processes using NAD+ and its other forms as substrates
Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine
Rapid Risk Reduction Seen in First Months The study found that semaglutide was associated with a 38% reduced risk of major adverse cardiovascular events (MACE) within the first 3 months compared to placebo (36 vs 58, respectively) Within the first 6 months, semaglutide was associated with a 41% reduced risk of MACE compared to placebo (67 vs 113, respectively) Notably, at 3 and 6 months, most patients had not yet lost much weight and many were not yet on the full target dose of semaglutide 2.4 mg weekly
If youre wondering whether you might be a good candidate for Mounjaro or other GLP-1 receptor agonists, this article provides the essential information you need to make an informed decision with your healthcare provider
